Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET AMPLIFICATION ( ENST00000318493.11 )
MET AMPLIFICATION ( ENST00000318493.11 )
Associated Disease
cancer
Source Database
CIViC Evidence
Description
Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1714
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/270
Rating
3
Evidence Type
Predictive
Disease
Cancer
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
25232318
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue